Introduction
During development, cell cycle progression is normally tightly coupled to the accumulation of cell mass (cell growth) (Neufeld and Edgar, 1998) ; however, in some adult postmitotic tissues, cell growth can become uncoupled from proliferation resulting in hypertrophic growth (Dorn and Force, 2005) . The molecular mechanisms that regulate hypertrophy and the means whereby proliferation and cell growth are normally coupled are poorly understood, but the fact that they are coupled during development suggests common regulatory mechanisms. One molecule that has been implicated in mediating both forms of growth in many tissues, including the heart, is c-Myc (Myc).
Myc is highly expressed in fetal, proliferating cardiac myocytes. However, soon after birth the myocytes cease to divide corresponding with the downregulation of Myc. Transgenic mice that overexpress Myc in the fetal myocardium develop ventricular enlargement secondary to myocyte hyperplasia, suggesting that Myc is sufficient to induce proliferative growth in the heart as well (Jackson et al, 1990) . Although Myc is not expressed in the adult heart under normal physiological conditions, it is upregulated rapidly in response to virtually all hypertrophic stimuli (Izumo et al, 1988) but the growth response is limited to hypertrophy and not hyperplasia (Soonpaa and Field, 1997) . The importance of Myc in mediating this hypertrophic growth in postmitotic myocytes is controversial but several lines of evidence support the concept that Myc can mediate cellular growth in the absence of cell division. In Drosophila, decreased expression of dMyc, the ortholog of mammalian Myc, in wing imaginal disc cells reduced cell proliferation and cell size (Johnston et al, 1999) . In contrast, dMyc overexpression resulted in increased cell size without affecting cell division. In mammalian cells, deleting Myc in B cells and hepatocytes reduced cell size (Iritani and Eisenman, 1999; Baena et al, 2005) . Conversely, previous studies from our lab demonstrated that activation of Myc specifically in adult myocardium was sufficient to induce hypertrophic growth and this growth was accompanied by cell cycle reentry (Xiao et al, 2001) . Similarly, overexpression of Myc in B lymphocytes both in vitro (Schuhmacher et al, 1999) and in vivo (Iritani and Eisenman, 1999) is also associated with an increase in cell size, independent of cell cycle progression.
The mechanisms whereby Myc regulates hypertrophic growth are less clear but it is interesting to note that genes responsible for Myc's ability to promote cell cycling have also been implicated in regulating cell size in certain contexts. Myc activation in the heart is accompanied by the upregulation of Cyclin D2 (CycD2) and cyclin-dependent kinase (Cdk) -2 and -4 activities (Xiao et al, 2001) . The link between this Myc-induced Cdk activity and Myc-induced proliferation has been well established (Amati et al, 1998) . Myc stimulated Cdk2 kinase activity, which is critical for cell cycle progres-sion (Amati et al, 1998) , occurs in large part by antagonizing the association of CdkIs, p27 and p21, with Cdk2 (Bouchard et al, 1999; Perez-Roger et al, 1999) . Upregulation of Myc target genes Cdk4 and CycD2 (Coller et al, 2000) leads to the rapid sequestration of p21 and p27, liberating Cdk2.
Consistent with this model, cells from CycD2
À/À mice, unlike wild-type controls, do not reenter the cell cycle in response to Myc (Bouchard et al, 1999) . The role of CycD2 in mediating Myc-induced hypertrophic growth was not addressed in these studies. Interestingly, CycD and Cdk4 have also been implicated in regulating cell size in Drosophila but, similar to Myc, the effect of CycD-Cdk4 overexpression varied according to cell type (Datar et al, 2000) . In undifferentiated proliferating cells, CycD/Cdk4 overexpression caused accelerated cell division (hyperplasia) without affecting cell size (Datar et al, 2000) . However, in differentiated cells, CycD/Cdk4 caused cell enlargement (hypertrophy), potentially through Rb-independent pathways. More recent studies have suggested that CycD/Cdk4 stimulates cell growth through regulation of mitochondrial activity (Frei et al, 2005) . In mammals, numerous studies have implicated CycD/Cdk4 in regulating cardiac hypertrophy; however, this connection is, so far, based primarily on cell culture experiments. Hypertrophic signals upregulate CycD2 expression and CycD-dependent kinase activity in the cardiac myocytes (Li et al, 1998; Busk et al, 2002) . Although forced expression of CycD2 in cardiac myocytes provoked cell division and not hypertrophy (Busk et al, 2005; Pasumarthi et al, 2005) , CycD2 was overexpressed at a developmental time point where the myocytes were still capable of reentering the cell cycle. Overexpression of CycD2 in adult, postmitotic cardiac myocytes has not been reported. However, inhibiting G1-Cyc/Cdk activity in adult myocytes blocks hypertrophic growth (Nozato et al, 2001) .
To determine the role of Myc in regulating hypertrophic growth specifically in adult, postmitotic myocardium and whether its growth effects are mediated through CycD2-dependent pathways in the heart, we developed inducible, cardiac-restricted Myc-deficient mice and a model of inducible, myocardial-specific Myc expression in a CycD2-null background. Deletion of Myc attenuated hypertrophic growth in response to both hemodynamic and pharmacologic hypertrophic stimuli and resulted in an increase in cardiac apoptosis. Myc-induced hypertrophic growth was dependent on the presence of CycD2 similar to what has been reported for Myc-induced cell cycle reentry, but was independent of Cdk2 activity.
Results
Creation of inducible, cardiac-specific Myc-deficient mice The role of Myc in cell cycle control and cellular proliferation has been well studied and Myc has been shown to be critical for the regulation of mammalian body size during development by controlling cell number (Trumpp et al, 2001) . However, Myc is also expressed in many adult tissues in pathological conditions, including cardiac hypertrophy, where cell growth but not cell division occurs. Myc's role in regulating normal physiology in these adult tissues remains unknown. To explore the role of Myc in cardiac hypertrophy in vivo, we created inducible Myc-deficient mice where Myc can be specifically deleted in adult myocardium with a tamoxifen-regulated Cre, MerCreMer (MCM). When Cre is activated in these mice (MCM;Myc fl/fl ) with 4-hydroxytamoxifen (4-OHT), the resulting recombination excises Myc coding exons 2 and 3 ( Figure 1A ). This deletion can be identified with DMycfl primers, which give a B600 bp product when recombination has occurred (de Alboran et al, 2001) . PCR performed on total ventricular DNA from control
) mice with DMycfl primers demonstrated no spontaneous recombination in the absence of ligand. However, 4-OHT treatment resulted in recombination in the ventricles of MCM;Myc fl/fl mice ( Figure 1B ). This recombination only occurred in the hearts of the 4-OHT-treated, MCM;Myc fl/fl mice and was not seen in other tissues ( Figure 1C ). As Myc is expressed at very low levels in adult myocardium at baseline, its expression was induced by subjecting mice to hemodynamic or pharmacological hypertrophic stimuli in vivo. MCM;Myc fl/fl mice with or without 4-OHT treatment underwent Sham or transverse aortic constriction (TAC) operation to induce cardiac hypertrophy. TAC induced a 9.7-fold increase in Myc protein expression in vehicle-treated MCM;Myc fl/fl mice when compared to Sham-operated mice. Pretreatment of MCM:Myc fl/fl mice with 4-OHT reduced the expected increase in Myc protein after hemodynamic load by 66.5% (9.6770.44-versus 3.2472.11-fold, Po0.005; Figure 1D ). This degree of recombination is consistent with previous reports using the MCM mice (Sohal et al, 2001 ) and likely reflects in part, that the heart consists of a number of different cell types although the majority of the protein arises from authentic cardiac myocytes. To confirm this finding, we analyzed Myc expression in total ventricular RNA prepared from treated Figure 2B ) with intact Myc expression demonstrated the expected increase in HW/BW ratio after TAC. In contrast, the hypertrophic response in Myc-deficient mice was attenuated. To confirm that the reduced HW/BW ratio in Myc-deficient hearts after pressure-overload represented a reduction in cell growth, we measured cardiac myocyte fiber width on wheat germ agglutinin-stained myocardial sections in these animals ( Figure 3A ). Cardiac myocyte width was 45% greater in control vehicle-treated MCM;Myc fl/fl subjected to TAC compared with 4-OHT-treated MCM;Myc fl/fl mice (17.587 0.33 versus 12.0870.28 mm, Po0.01; Figure 3B ). Consistent with this reduction in cardiac hypertrophy, Myc-deficient mice also showed attenuated upregulation of hypertrophic marker genes such as atrial natriuretic factor (ANF) and b-myosin heavy chain (bMHC) mRNA compared with untreated MCM:Myc fl/fl mice after TAC ( Figure 3C ). Interestingly, there was a significant increase in interstitial fibrosis as measured by picrosirius red staining of ventricular sections from 4-OHT treated MCM;Myc fl/fl mice subjected to Sham versus TAC (1.0070.04 versus 1.4870.09-fold, Po0.01; Figure 4A and B). To determine if this was in response to cell loss, we assessed apoptosis by TdT-mediated dUTP-biotin nick-end labeling (TUNEL) staining. Apoptotic cardiomyocytes were rarely detected in MCM;Myc fl/fl mice with or without 4-OHT treatment mice that underwent sham operation. However, apoptosis increased 12-fold in 4-OHTtreated MCM;Myc fl/fl mice subjected to TAC compared to untreated Sham animals (Po0.001; Figure 4C ), suggesting Myc was also necessary for cardiac myocyte survival with hypertrophic stimuli.
Myc-deficient mice display reduced cardiac growth and increased apoptosis with chronic isoproterenol infusion
To determine if this attenuated hypertrophy and fibrosis was a general response to hypertrophic stimuli, we treated MCM: Myc þ / þ or MCM;Myc fl/fl mice with 4-OHT for 5 days and then subjected the mice to an infusion of ISO or vehicle for 1 week. ISO stimulation resulted in a 30.4% increase in HW/BW ratio in 4-OHT-treated MCM:Myc þ / þ mice compared to only a 17.4% increase in ISO-treated, Myc-deficient MCM;Myc fl/fl mice (Po0.05; Figure 5A ). ISO stimulation increased heart-to-body weight ratio in 4-OHT-treated control MCM:Myc þ / þ mice (5.1770.12 versus 6.7470.40 mg/g, Po0.01; Figure 5A ). In contrast, MCM;Myc fl/fl mice demonstrated no significant increase (4.8370.62 versus 5.677 0.33 mg/g, P ¼ NS). This difference in HW/BW ratio was paralleled by a 19.4% increase in cardiac myocyte fiber width in ISO-stimulated MCM:Myc þ / þ mice when compared to fiber width in vehicle-treated MCM:
Myc fl/fl hearts (13.7970.56 versus 11.5570.30 or 11.0470.14 mm, Po0.01; Figure 5B ). There was no significant increase in cardiac myocyte fiber width in ISO-treated MCM; on sections of ventricular tissue. As shown, ISO-treated MCM;Myc fl/fl ventricles displayed a 6.3-fold increase in TUNEL þ ve nuclei (Po0.01; Figure 5D ), suggesting that Myc was also necessary for cardiac myocyte survival with hypertrophic stimuli.
Inhibition of Myc in vitro blocks ET-1-stimulated hypertrophic growth and CycD2 upregulation
To explore the mechanisms underlying the growth effects of Myc in cardiac myocytes, we utilized an in vitro model of hypertrophic growth by stimulating neonatal rat ventricular myocytes (NRVMs) with endothelin-1 (ET-1). NRVMs were serum starved for 48 h and then exposed to ET-1, which upregulates Myc expression ( Figure 6A ) and induces hypertrophic growth (Figure 6Ba versus b) without increasing cell number (data not shown). To confirm our in vivo results, we blocked ET-1-induced Myc expression with an adenovirus overexpressing an siRNA to Myc (Ad-siMyc). Overexpressing a control protein (Ad-LacZ) or scrambled siRNA sequence (data not shown) had no effect on Myc induction.
Myc is well known to regulate the expression of a number of G1 cyclins and Cdk activities. As these proteins are also regulated in cardiac myocytes after hypertrophic agonists, we examined the expression of a panel of cell cycle activators ( Figure 6A ). Although stimulation of NRVMs with ET-1 upregulated CycD2 leading to increased Cdk2 and 4 activity, these changes were blocked by inhibiting Myc expression ( Figure 6A ). Inhibiting ET-1-induced Myc expression also prevented the expected increase in myocyte size ( Figure  6Bb versus d) presumably though the inhibition of Mycdependent protein synthesis seen in control myocytes after ET-1 stimulation (1.0070.05 versus 1.5470.18, Po0.01; Figure 6C ). Although ET-1 induced both ANF and b-MHC, the expression of these hypertrophic markers was attenuated by inhibiting Myc expression, similar to the in vivo results ( Figure 6D ). It is well known that Cdk2 and 4 activity cooperate for Myc-induced cell cycle progression but the role of these proteins in mediating Myc-induced hypertrophic growth is unknown.
CycD2 is necessary for Myc-induced cardiac hypertrophy
Our previous studies had demonstrated that cardiac-specific activation of Myc in adult a-MHC-MycER mice with 4-OHT could stimulate both cardiac myocyte hypertrophy and cell cycle reentry but not proliferation when compared to similarly treated nontransgenic (NTg) littermates (Xiao et al, 2001) . To determine if Myc-induced hypertrophic growth was CycD2 dependent, as has been described for Mycinduced cell cycle entry (Bouchard et al, 1999; Perez-Roger et al, 1999) , we created MycER mice deficient for CycD2. Although Myc activation induced CycD2 expression and Cdk2 and 4 activity in MycER myocardium, no upregulation was seen in similarly treated CycD2-null mice ( Figure 7A ). Treatment of MycER;CycD2 þ / þ mice with 4-OHT for 1 week resulted in a 26.6% increase in HW/BW ratio (4.3670.17 versus 5.5270.19, Po0.01; Figure 7B ). However, activation of Myc in CycD2-null mice did not result in a significant change in cardiac mass (4.5170.11 versus 4.5370.19, P ¼ NS; Figure 7B ). Likewise, the 85-fold increase in BrdUpositive nuclei in MycER;CycD2 þ / þ seen after 4-OHT activation of Myc (0.0370.03 versus 2.5470.8; Po0.01) was abolished in MycER;CycD2 À/À mice (0.0470.03 versus 0.3570.11, P ¼ n.s.; Figure 7C and D).
Myc-induced cell cycle reentry but not hypertrophic growth is Cdk2 depend-
To clarify if the lack of hypertrophic growth in MycER; CycD2 À/À mice was due to a lack of CycD2 and potentially Cdk4 activity versus the inability to upregulate Cdk2 activity in these hearts, we examined the role of Cdk2 and Cdk4 in Myc-induced hypertrophic growth and protein synthesis in vitro. NRVMs infected with an adenovirus overexpressing Myc (AdMyc) increased Cdk2 activity and to a lesser extent Cdk4, similar to its effects in vivo ( Figure 8A ). To block Cdk activity, we coinfected AdMyc cultures with a dominantnegative Cdk2 (Ad-dnCdk2) or Cdk4 (Ad-dnCdk4) virus. These vectors specifically blocked Myc-induced activation Cdk2 or 4 activity ( Figure 8A ). The effect of these interventions on cardiac myocyte cell size was assessed with forward scatter by flow cytometry. Forced expression of Myc increased NRVM forward scatter from 420.57103.3 to 474.07119.8 indicating larger NRVMs. Although inhibition of Cdk2 activity had no effect on Myc-induced hypertrophic growth (470.27120.7), blocking Cdk4 activity attenuated Myc-induced hypertrophy (439.5797.7). Similarly, overexpression of Myc induced protein synthesis by 47% as measured by [ 3 H]phenylalanine incorporation, which was not affected by inhibiting Cdk2 activity but was prevented by blocking Cdk4 activity ( Figure 8C ). In contrast, both Ad-dnCdk2 and Ad-dnCdk4 inhibited the Myc-induced 6.2-fold increase in DNA synthesis (6.2371.23 versus 1.1870.4 or 3.6470.33-fold, Po0.01; Figure 8D ), suggesting that while Myc-dependent reactivation of DNA synthesis in cardiac myocytes requires both Cdk2 and 4, Myc-stimulated cell growth is Cdk2 independent.
Discussion
We have previously shown that overexpression of Myc is sufficient to induce cardiac hypertrophy in adult myocardium (Xiao et al, 2001 ). However, whether Myc is also necessary for cell growth and the mechanisms whereby Myc might induce cardiomyocyte hypertrophy remained unknown. In the present study, we investigated Myc's role in cardiac hypertrophy by inactivating Myc both in vivo and in vitro. The results demonstrate that an Myc-Cyclin D2-dependent pathway is required for hypertrophic growth in cardiac myocytes. Deleting Myc in adult myocardium attenuated but did not block cardiac hypertrophy completely. This reduction in cardiac myocyte size was accompanied by a reduction in fetal gene markers normally upregulated in hypertrophic hearts, suggesting that the entire hypertrophic phenotype, not just growth, was suppressed. In contrast, inhibition of Myc in cultured cardiac myocytes completely abolished the hypertrophic response induced by ET-1. One explanation for this divergent response may simply be related to simple technical differences between the two models. ET-1 predominantly stimulates G-protein-coupled, endothelin-A receptors in cardiac myocytes, which activate a downstream signaling cascade mediated by the G(q) heterotrimeric G proteins (Sugden and Clerk, 2005) . In contrast, TAC initiates a host of direct and indirect autocrine and paracrine neurohumoral factors, which have been implicated in mediating cardiac growth (Dorn and Force, 2005) . It is also possible that the relative role of Myc in the various forms of cardiac hypertrophy explored here varies. Additionally, the time course of the two models differed greatly. The in vitro experiments determined the relative importance of Myc to protein synthesis at an early time point when Myc is highly expressed. In contrast, the in vivo studies compared hypertrophic responses after 1 and 2 weeks of hemodynamic stress. It is possible that Myc is more important to the initial hypertrophic response and that later redundant mechanisms are able to at least partially compensate. This may explain why the observed attenuation of hypertrophy was greater in the shorter, ISO-stimulated model. The finding that Myc was important for myocyte survival in hypertrophy was unexpected. Hypertrophic agonists led to a small, but significant increase in apoptosis in Myc-null hearts that resulted in increased interstitial fibrosis. One of the paradoxes facing investigators studying Myc function is the observation that both Myc over-and underexpression results in apoptosis. Of the two, Myc-induced apoptosis has been studied in much more detail (Pelengaris et al, 2002) . Ectopic expression of Myc sensitizes cells to a wide range of apoptotic stimuli including tumor necrosis factor-alpha (TNFa) (Klefstrom et al, 1994) by inducing cytochrome c (Morrish et al, 2003) release from the mitochondrial inter- membrane space into the cytosol where it can promote apoptosis (Iaccarino et al, 2003) . The link between Myc deficiency and apoptosis is less clear, but may also be mediated through a mitochondrial pathway. A large proportion of the nuclear-regulated mitochondrial genes are direct Myc targets (Morrish et al, 2003) , and are induced in cells upon growth stimulation. Ensuring that the cell maintains the correct stoichiometry of respiratory complex subunits and their correct assembly in the mitochondria is critical for adapting to the increased metabolic demands associated with cell growth (Poyton and McEwen, 1996) . Disruption of this balance can have detrimental effects, and examples exist of mitochondrial dysfunction that result from both reduced (Schapira and Cock, 1999) or increased expression of genes involved in mitochondrial function, such as adenine nucleotide translocase-1 (Bauer et al, 1999) and the mitochondrial hinge protein (Okazaki et al, 1998) . Therefore, Myc underexpression could lead to mitochondrial dysfunction and apoptosis by deregulating genes involved in mitochondrial function.
A major finding of this study is that a CycD2-dependent pathway mediates Myc-induced hypertrophic growth, although the end effectors remain unclear. It is generally accepted that Cdk2 kinase activation is an essential step in Myc-induced G1-exit and that induction of CycD2 is a critical preliminary step in this process, as the newly formed CycD/ Cdk4 complexes sequester Cdk inhibitors p27 and p21 (Bouchard et al, 1999; Perez-Roger et al, 1999) . We found that both Myc-induced cardiac cell cycle entry and cellular growth was blocked in CycD2-null mice. However, in contrast to its effects on cell cycle progression, Myc-induced hypertrophic growth was independent of Cdk2 activity. These results are consistent with the preferential role of Cdk2 in cardiac hyperplasia not hypertrophy, shown by forced expression in vivo (Liao et al, 2001 ). Given that Cdk2 is critical for Myc's proliferative effects, whether CycD2 leads to proliferation or hypertrophy might be dependent on whether excess Cdk inhibitors are present. Thus, the differential growth effect of CycD2 in proliferative versus postmitotic cells may be attributable to a developmental increase in Cdk inhibitors, as is seen in the postnatal heart . This report represents the first evidence that Mycdependent hypertrophic growth is also CycD2 dependent and that the pathways controlling cell cycle progression and cellular growth diverge at CycD.
Several lines of evidence suggest that G1 cyclins and Cdks might be critical for the control of cell growth. In Drosophila, CycD/Cdk4 stimulates and controls cell growth in postmitotic cells (Datar et al, 2000) . This CycD/Cdk4-induced cell growth was dependent on a gene encoding the mitochondrial ribosomal protein, mRpL12 (Frei et al, 2005) . In the absence of mRpL12, cells demonstrated reduced growth and mitochondrial activity suggesting that CycD/Cdk4 controls cell growth via a mitochondrial-dependent pathway. A number of reports have implicated CycD/Cdk4 in regulating cardiac hypertrophy in mammalian cells as well, although the downstream effectors have not been identified (Busk et al, 2002; Tamamori-Adachi et al, 2002) . Likewise, several reports have documented that inhibiting G1-Cyclin/Cdk activity in adult, postmitotic cardiac myocytes can attenuate hypertrophic growth (Tamamori et al, 1998; Nozato et al, 2001 ). We recently demonstrated that cardiac hypertrophy is accompanied by increased RNA polymerase (pol) III transcription, which is related to changes in both the activity and level of the RNA pol III-specific transcription factor TFIIIB (Goodfellow et al, 2006) . Myc can potentiate TFIIIB activity directly by binding and activating transcription (GomezRoman et al, 2003) or potentially indirectly, by removing the inhibiting effects of the retinoblastoma gene product (Rb). Hypophosphorylated, active Rb binds TFIIIB and prevents its interactions with TFIIIC or RNA pol III (Larminie et al, 1997) . Myc-induced Cdk activity could potentially remove this inhibitory effect. Given the fundamental role Myc plays in regulating cell growth, it will be critical in future studies to determine the role and mechanisms whereby CycD/Cdk4 might induce cardiac hypertrophy. 
Materials and methods

Transgenic mice and animal studies
The inducible a-myosin heavy chain (a-MHC)-MycER transgenic mice have been described (Xiao et al, 2001) . Myc-floxed mice (Myc fl/fl ) were provided by Dr F Alt and genotyped as described (de Alboran et al, 2001) . The tamoxifen-inducible MerCreMer (MCM) mice were generated by Dr J Molkentin under the control of the a-MHC promoter (Sohal et al, 2001 ). To activate Myc or Cre in these transgenic mice, 1 mg of 4-OHT (Sigma) dispersed in peanut oil by sonication was injected intraperitoneally daily. Control littermates were injected with peanut oil alone. To induce excisional recombination of Myc, mice were treated with 4-OHT for 5 days. To identify recombination, PCR conditions were chosen for DMycfl primers that do not amplify the 42.5 kb fragment in wild-type mice and no product is obtained. CycD2-deficient mice were a kind gift from Dr P Sicinski (Sicinski et al, 1996) . All mice were maintained on a C57 (MycER, CycD2) or FVB (MCM;Myc fl/fl ) background. Animals were handled in accordance with institutional guidelines.
For TAC, a fixed pressure overload was obtained by surgically constricting the transverse aorta, as has been previously described (Rockman et al, 1994) . Age-matched Sham-operated animals underwent the identical surgical procedure, except that the aortic constriction was not placed. For the ISO infusion model, 7-day osmotic minipumps (Alzet, model 2001) loaded with 0.2 ml of ISO (28 mg/ml per 25 g body weight) were implanted into the subcutaneous space of 10-week-old mice via a small intrascapular incision.
Cell culture and adenovirus preparation NRVM were prepared as previously described (MacLellan et al, 2000) . For all cell culture experiments, NRVM were serum-starved in serum-free DMEM for 36 h before use. Construction of AdMyc (Mitchell and El-Deiry, 1999) , dnCdk2 and dnCdk4 (Ferguson et al, 2000) has been previously described. Viruses were propagated and titered according to established protocols (MacLellan et al, 2000) .
To create an siRNA adenovirus to Myc, a shuttle plasmid was constructed by inserting a 21-mer RNA oligonucleotide directed against the rat and mouse Myc sequence (5 0 -aagaggcggacacac aacgtc-3 0 ) into the unique ApaI and HindIII sites of pDC.silencer(U6), which was kindly supplied by Dr Abdellatif (Yue et al, 2004) . Adenoviruses were propagated and titered according to published protocols (MacLellan et al, 2000) . For cell culture experiments, NRVM were infected with adenoviruses 36 h before treatment.
Protein analysis
Western blots were performed on protein extracts from whole ventricles, according to established protocols (MacLellan et al, 2000) . Antibodies were obtained from Santa Cruz Biotechnology, Inc. unless otherwise noted. Protein expression was visualized using horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence reagents (Amersham Biosciences). Immune complex kinase assays for Cdk2 and Cdk4 activity were performed on 500 mg of ventricular lysates (Li et al, 1998) . The immunocomplexed pellet was incubated in 30 ml kinase buffer with 1 mg of Rb (Santa Cruz Biotech.) or histone H1 (Upstate Biotech, Inc.) substrate, 5 mCi of [g-32 P]ATP, 1 mM DTT and 5 mM ATP and then electrophoresed through 10% acrylamide gels.
Histology and morphometric analysis
Hearts were fixed overnight in 4% paraformaldehyde buffered with PBS and routinely processed. BrdU labeling was achieved by injecting 50 mg of BrdU per gram of body weight intraperitoneally. To identify DNA synthesis, paraffin-embedded sections were probed with antibodies against BrdU (Zymed). Antibody against sarcomeric myosin heavy chains (MF20; Developmental Hybridoma Studies Bank) and diamidinophenolindole (DAPI) were used according to the manufacturer's instructions. Apoptosis was determined using ApopTag fluorescein in situ apoptosis detection kit (Chemicon) or TACS TM 2 TdT blue label in situ apoptosis detection kit (Trevigen). Apoptotic cells were detected with fluorescein conjugate or visualized with an enzymatic reaction using the TUNEL method. The apoptosis rates were determined by examining 42500 cardiac nuclei per heart sections. Secondary antibodies were purchased from Molecular Probes. Myocyte fiber widths were measured on perfusion-fixed myocardial sections using a computerized morphometric system (SigmaScan, Systat Inc.). All myocytes were measured at the same magnification with the observer blinded to the genotype of the animals.
Northern blot analysis
Total RNA was isolated from ventricles using RNA STAT 60 Kit (TelTest, Inc.). Northerns blots were performed according to established protocols using radioactive (MacLellan et al, 2000) or digoxigenin (DIG)-labeled probes (MacLellan et al, 2000) . The oligonucleotide and cDNA probes used have been reported (Ross et al, 1998) .
Measurement of myocyte cell number, cell size, DNA and protein synthesis
To determine myocyte cell number, DNA and protein synthesis, serum-starved myocytes were infected with the indicated adenoviral vectors (50 PFU/myocyte). To determine cell number, myocytes were trypsinized and total cell counts determined using a Coulter Counter (Becton-Dickinson). To estimate protein synthesis, myocytes were labeled with 5 mCi/ml of [ 3 H]phenylalanine (Amersham Corp.) for 4 h after which cell precipitates were solubilized and counted. To determine the relative DNA synthesis, myocytes were cultured in media containing 5 mCi/ml of [ 3 H]thymidine (ICN) for 6 h and thymidine incorporation quantified. Flow cytometry to assess cell size was performed at the UCLA Flow Cytometry Laboratory based on forward scatter as previously described (Gylys et al, 2004) . Aliquots of 10 5 cells in 500 ml 1 Â PBS were dispensed into small conical tubes (Falcon). At least 10 000 events were collected before analysis. All samples were analyzed using a Becton Dickinson FACScan analytic flow cytometer (Becton Dickinson) with FCS Express software (DeNovo).
Statistical analysis
All data are presented as mean7s.e.m. except results of forward scatter, which are presented as mean7s.d. Results were compared by analysis of variance and Fisher's PLSD tests, using significance at a P-value o0.05.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
